Research programme: oncology kinase inhibitors - Arrien Pharmaceuticals

Drug Profile

Research programme: oncology kinase inhibitors - Arrien Pharmaceuticals

Alternative Names: ARN-1032; ARN-3015; ARN-3016; ARN-3020; ARN-3236; ARN-3261; ARN-5032; ARN-7016

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Arrien Pharmaceuticals
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Salt-inducible kinase-2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Breast cancer; Lung cancer; Prostate cancer
  • No development reported Diffuse large B cell lymphoma; Ovarian cancer

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for preclinical development in Diffuse large B cell lymphoma in USA
  • 04 Nov 2017 No recent reports of development identified for preclinical development in Ovarian-cancer in USA
  • 22 Jun 2017 Arrien Pharmaceuticals plans to initiate IND safety and toxicology studies for ARN 3261 for diffuse large B-cell lymphoma, ovarian, breast, prostate and lung cancers in the third quarter of 2017 (Arrien Pharmaceuticals pipeline, June 2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top